There’s no reason to assume that every branded drug will fall victim to the “patent cliff.” Actions taken before drug patent expiration can extend drug life cycles.
Posts published in “Insights”
Artificial intelligence is allowing chemists to find new way to synthesize drug molecules, and forcing drug developers to shore up their patent strategies.
Recently a presentation by an Israeli patent examiner was brought forward in an argument against patent evergreening. In her presentation, the patent examiner claims that patent evergreening has the following…
Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements
0
This article was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Ther Innov Regul Sci. 2019 Jan 7:2168479018811889 under a Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) Abstract A 505(b)(2)…
Historic drug sales data can help with market sizing. By examining sales trends over time you can gauge the attractiveness of the market entry. For patented drugs examining sales trends…
In evaluating generic entry opportunities many factors must be considered. DrugPatentWatch has comprehensive resources to aid in evaluating patent and regulatory constraints, and those are described in further detail in…
This article was originally published by Philippe Lahorte in World Patent Information Volume 54, Supplement, September 2018, Pages S18-S22 Under a Creative Commons license. Abstract This article provides an insight…
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’ market-leading platform, bringing together the most relevant information to support…
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.